ICML 2019 | New therapeutic directions in CTCL
Cutaneous T-cell lymphoma (CTCL) therapy has experienced a boost in recent times, such as the MAVORIC trial that led to the approval of mogamulizumab (NCT01728805). Here, Pierluigi Porcu, MD, Sidney Kimmel Cancer Center – Jefferson Health, discusses new therapeutic directions in CTCL. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
Get great new content delivered to your inboxSign up